This document lays down the non-clinical and clinical requirements for recombinant human follicle stimulating hormone (r-hFSH)-containing medicinal products claiming to be similar to another one already marketed.
Keywords: Follicle stimulating hormone (FSH), similar biological products, comparability, non-clinical studies, clinical studies
Current effective version
Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle-stimulating hormone (r-hFSH)
This guideline lays down the non-clinical and clinical requirements for recombinant human follicle stimulating hormone (r-hFSH)-containing medicinal products claiming to be similar to another one already marketed.
English (EN) (106.75 KB - PDF)
Document history - First version (current)
Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle-stimulating hormone (r-hFSH)
This guideline lays down the non-clinical and clinical requirements for recombinant human follicle stimulating hormone (r-hFSH)-containing medicinal products claiming to be similar to another one already marketed.
English (EN) (106.75 KB - PDF)
Overview of comments on guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle-stimulating hormone (r-hFSH) (EMA/CHMP/BMWP/671292/2010)
English (EN) (85.84 KB - PDF)
Draft guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle stimulating hormone (r-hFSH)
This guideline lays down the non-clinical and clinical requirements for recombinant human follicle stimulating hormone (r-hFSH)-containing medicinal products claiming to be similar to another one already marketed.
English (EN) (159.06 KB - PDF)
Concept paper on similar biological product containing recombinant follicle stimulation hormone
English (EN) (125.31 KB - PDF)
Related content
- Multidisciplinary: biosimilar
- Directive 2001/83/EC
- Good pharmacovigilance practices (GVP) module V – risk management systems
- ICH S6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals
- Immunogenicity assessment of biotechnology-derived therapeutic proteins
- Investigation of bioequivalence
- Similar biological medicinal products
- Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues
- Similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues